Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs

Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs

Purpose: To accurately ascertain the frequency of pathogenic germline variants (PGVs) in a pan-cancer patient population with universal genetic testing and to assess the economic impact of receiving genetic testing on healthcare costs. Methods: In this prospective study, germline genetic testing usi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Adrienne T. Perkins, Derrick Haslem, Jessica Goldsberry, Katherine Shortt, Laura Sittig, Sharanya Raghunath, Christopher Giauque, Shawnee Snow, Gail Fulde, Bryce Moulton, David Jones, Lincoln Nadauld
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
hereditary cancer
healthcare costs
precision oncology
pathogenic germline variants
germline testing
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/caf8a4a6468242518ce58803bfb254a7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/caf8a4a6468242518ce58803bfb254a7

Ejemplares similares